University of Southampton.
Professor Tim Elliott is Professor of Experimental Medicine within Medicine at the University of Southampton. Professor Tim Elliott left the University of Oxford with a first in Biochemistry in 1983, received a PhD from the University of Southampton in 1986 and completed his postdoctoral training at MIT. He held a lectureship and later a professorship in immunology (Weatherall Institute for Molecular Medicine and Balliol College, University of Oxford) between 1990-2000 before being appointed to the Chair of Experimental Oncology, School of Medicine, University of Southampton. He was Associate Dean (Research) for the Faculty of Medicine between 2005 and 2015. He’s held appointments on Scientific Advisory boards at the Wellcome Trust, the Association of International Cancer Research, Leukaemia and Lymphoma Research, and Symphogen, and currently chairs the CRUK Expert Review Group for Cancer Immunology He has published over 130 papers (h-index, 48) in the field of molecular immunology; was visiting lecturer of the Alberta Heritage Foundation for Medical Research, University of Edmonton, Alberta in 1999; and recently held a visiting Professorship at the Netherlands Cancer Institute, Amsterdam. He is a fellow of the Royal Society of Biology and in 2014 he was elected to the Academy of Medical Sciences. Professor Elliott was amongst the key group of immunologists who developed studies of antigen presentation at the molecular level during the 1980s, undertaking a series of studies to determine and define the immunostimulatory properties of MHC Class I molecules and elucidating the molecular mechanisms of co-factor assisted peptide loading of MHC Class I in antigen presenting cells: work considered to be the fundamental foundation of much of the recent work on antigen presentation. The work underpins rational T-cell based vaccine design and continues to fuel translational research in Southampton where discoveries in the areas of antigen discovery, T cell regulation and immunodominance are making a significant impact on new and ongoing cancer immunotherapy trials. His mechanistic studies have always benefitted from an active interface with the physical sciences including collaborations with synthetic and computational chemistry and recently with Microsoft UK. He developed a 4 year integrated PhD programme in Biomedical Science which is now in its eleventh year.
Immunology,Immunotherapy,Experimental Medicine, Experimental Oncology